farglitazar

Ligand id: 2672

Name: farglitazar

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 101.66
Molecular weight 546.22
XLogP 7.13
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

References
1. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM. (1998)
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
J. Med. Chem., 41 (25): 5020-36. [PMID:9836620]
2. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, Nelson MT. (2005)
Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.
Pharmacology, 73 (1): 15-22. [PMID:15452359]
3. Willson TM, Brown PJ, Sternbach DD, Henke BR. (2000)
The PPARs: from orphan receptors to drug discovery.
J. Med. Chem., 43 (4): 527-50. [PMID:10691680]
4. Yu C, Chen L, Luo H, Chen J, Cheng F, Gui C, Zhang R, Shen J, Chen K, Jiang H, Shen X. (2004)
Binding analyses between Human PPARgamma-LBD and ligands.
Eur. J. Biochem., 271 (2): 386-97. [PMID:14717706]